Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_assertion description "[Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_assertion evidence source_evidence_literature NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_assertion SIO_000772 15946589 NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_assertion wasDerivedFrom befree-20150227 NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_assertion wasGeneratedBy ECO_0000203 NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.
- befree-20150227 importedOn "2015-02-27" NP614161.RAlgEjI9kL_zKyAk_zDKq0hp9gkx9WEadVur9BRuvUM4Y130_provenance.